Invitae Corporation
NVTA
株式のランク
#35781
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
株価
$0.016
最終同期: 2024-03-11
時価総額
$3.27M
変化（1日）
-5.33%
変化（1年）
5,233.33%
国
US
取引 Invitae Corporation (NVTA)
カテゴリー
Healthcare
Invitae Corporation（NVTA）の利益
Sep 2023 時点の利益 TTM: $-1.45B
Invitae Corporation の最新の財務報告によると、同社の現在の利益は $-1.45B です。2022 年には $-3.15B の利益を上げ、これは 2021 年の利益 $-415.86M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Invitae Corporation の利益の推移（2016 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-1.45B | -100.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $-3.15B | 657.75% |
| 2021 | $-415.86M | -41.78% |
| 2020 | $-714.27M | 174.28% |
| 2019 | $-260.42M | 97.05% |
| 2018 | $-132.16M | 5.52% |
| 2017 | $-125.24M | 24.92% |
| 2016 | $-100.26M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.61B | -623.31% |
US
|
|
| $4.76B | -427.50% |
US
|
|
| $-252.70M | -82.62% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -214.03% |
US
|
